Open AccessTumor markers CA 19‐9 and CA 195 are also useful as markers for cystic fibrosis
Author(s) -
Wu James T.,
Olson June,
Walker Kay
Publication year - 1992
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.1860060310
Subject(s) - ca19 9 , sputum , epitope , cystic fibrosis , exacerbation , carcinoembryonic antigen , lung cancer , carcinoma , lung , bronchiectasis , monoclonal antibody , medicine , gastroenterology , antigen , pathology , antibody , immunology , pancreatic cancer , cancer , tuberculosis
Abstract When monoclonal kits are used we can no longer detect highly elevated serum concentrations of carcinoembryonic antigen in cystic fibrosis (CF) patients as we could earlier ( Pediatr Res 10:235–236, 1975). Instead, we find increased concentrations of CA 19‐9 or CA 195 in the CF sera. The serum levels of CA 19‐9 not only reflect the pulmonary condition of CF patients but also respond well to antibiotic therapy. Several lines of evidence suggest that the elevated serum concentration of CA 19‐9 is derived from sputum and corresponds with the amount of sputum in the lung. Correlations between CA 19‐9 and CA 195 in random and serial specimens from both patients with CF and patients with pancreatic carcinoma suggest that all sera contain heterogeneous, Lewis blood group‐related epitopes and the proportions of various epitopes are different among individual patients. When monitored on multiple tumor markers, the pattern of CF is different from that of pancreatic carcinoma although both usually show elevated CA 19‐9. Our study indicates that both CA 19‐9 and CA 195 can be used as sensitive markers for the early detection of exacerbation in CF patients. © 1992 Wiley‐Liss, Inc.